Olezarsen

Details

Olezarsen (formerly AKCEA-APOCIII-LRx / ISIS 703802) is a GalNAc (N-acetylgalactosamine)-conjugated antisense oligonucleotide (ASO) developed by Ionis Pharmaceuticals that targets APOC3 (apolipoprotein C-III) messenger RNA. The GalNAc conjugate enables hepatocyte-selective delivery via the asialoglycoprotein receptor, reducing the systemic immunological burden and thrombocytopenia risk compared to earlier unconjugated ASOs (e.g., volanesorsen). Administered as a monthly subcutaneous injection.

• Class: Antisense oligonucleotide (ASO); GalNAc-conjugated
• Target: APOC3 (APOC3 mRNA → hepatic apolipoprotein C-III)
• Route/Dose: Subcutaneous; 50 mg or 80 mg monthly (phase 3 doses)
• Regulatory status: FDA-approved for familial chylomicronemia syndrome (FCS); ESSENCE-TIMI 73b data supports potential label expansion to moderate hypertriglyceridemia
• Developer/Sponsor: Ionis Pharmaceuticals

Key Facts

Mechanism of Action

• GalNAc conjugation delivers ASO payload selectively to hepatocytes via asialoglycoprotein receptor-mediated endocytosis
• ASO hybridizes to APOC3 mRNA in the liver → mRNA degradation (RNase H-mediated) → markedly reduced hepatic APOC3 protein synthesis
• Reduced APOC3 → restored LPL activity (less LPL inhibition) + enhanced hepatic remnant uptake → accelerated clearance of TG-rich lipoproteins (VLDL, IDL, chylomicron remnants)

FCS Indication — BALANCE Trial

• Olezarsen demonstrated significant reduction in TG levels and acute pancreatitis episodes in patients with FCS (TG typically >1000 mg/dL, monogenic LPL-pathway defects)
• FDA-approved for FCS — first GalNAc-ASO approved for a lipid disorder
• Preceded volanesorsen (unmodified ASO, EMA-approved for FCS but rejected by FDA due to thrombocytopenia)

Phase 3 RCT — ESSENCE-TIMI 73b (Moderate HTG)

• Phase 3, double-blind, placebo-controlled; n=1,349; moderate HTG (TG 150–499 mg/dL) + elevated CV risk; 160 sites; 12 months sources/olezarsen-essence-timi73b-nejm-2025 (high)
• 6-month TG reduction (placebo-adjusted): −58.4 pp (50 mg; P<0.001) and −60.6 pp (80 mg; P<0.001)
• TG normalization (<150 mg/dL) at 6 months: 85.0% and 88.7% vs 12.5% placebo
• 12-month TG reduction: −50.7 pp sustained (both doses)
• APOC3 reduction: 62% (50 mg) and 70% (80 mg)
• Remnant cholesterol: reduced up to ~70% (80 mg) — largest anti-remnant effect of any agent studied
• ApoB: reduced ~15% — total atherogenic particle burden
• LDL-C: unchanged — mechanistically expected
• No CV outcomes data: Trial not powered for MACE

Safety Profile

• Injection-site reactions: more common than placebo; predominantly mild
• Aminotransferase elevations: mild (>ULN any degree) more common (34–38% vs 18%); no excess of clinically significant (>3× or >5× ULN) elevations; no Hy's law cases — hepatic safety maintained
• Thrombocytopenia: platelet <100K/µL ~2.2–2.3% vs 0.8% placebo (NS); much improved vs parent compound volanesorsen; no safety stopping rules triggered in any patient
• Glycated hemoglobin: small increase in patients with pre-existing diabetes mellitus; no change in insulin resistance or beta-cell function
• Serious adverse event frequency comparable to placebo

Comparator APOC3 Agent — Plozasiran (siRNA)

• Both olezarsen (ASO) and plozasiran (siRNA) target APOC3 with broadly similar efficacy (~58–79% APOC3 reduction, ~44–62% TG reduction in their respective studied populations)
• Different modalities: ASO vs siRNA; different dosing schedules; no head-to-head data
• Both share class-specific mild safety signals (transaminase elevations, modest HbA1c increase in diabetics)

Contradictions / Open Questions

• CV outcomes unproven in moderate HTG: APOC3 genetic LOF data strongly support ASCVD benefit, but ESSENCE-TIMI 73b was not powered for MACE — a dedicated outcomes trial is needed sources/olezarsen-essence-timi73b-nejm-2025 (high)
• Optimal dose selection: 50 mg and 80 mg showed nearly identical efficacy (−58 vs −61 pp TG); 80 mg had more aminotransferase elevations; dose selection in clinical practice will balance efficacy vs safety monitoring
• Long-term data: Only 12 months in ESSENCE-TIMI 73b; long-term extension data being collected in FCS program; duration of TG control and safety beyond 1 year not established
• Fibrate co-use: Post-hoc signal of possible enhanced TG lowering with concurrent fibrate — biological plausibility (complementary LPL-related mechanisms) but attributed to chance in the trial; pending data from severe HTG trials

Connections

• Related to concepts/APOC3-Inhibition — class mechanism, genetic evidence, comparator agents
• Related to concepts/Hypertriglyceridemia-Management — clinical positioning and treatment algorithm
• Related to concepts/Dyslipidemia-Management — role in broader dyslipidemia framework
• Related to concepts/Gene-Silencing-Therapy — ASO as a gene-silencing therapeutic modality

Sources

• sources/olezarsen-essence-timi73b-nejm-2025 — ESSENCE-TIMI 73b Phase 3 RCT; primary efficacy and safety data in moderate HTG